Amylyx Pharmaceuticals, Inc. Shares Outstanding (Cover Page)
Amylyx Pharmaceuticals, Inc. (AMLX) had Shares Outstanding (Cover Page) of 111.42 million shares as of 2026-07-27, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-06
- 2026-07-27: Entity Common Stock, Shares Outstanding 111.42M shares.
- 2026-04-27: Entity Common Stock, Shares Outstanding 111.19M shares.
- 2026-02-23: Entity Common Stock, Shares Outstanding 110.54M shares.
- 2025-10-27: Entity Common Stock, Shares Outstanding 109.82M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-07-27 | 111.42M shares 10-Q · filed 2026-08-06 |
| 2026-04-27 | 111.19M shares 10-Q · filed 2026-05-07 |
| 2026-02-23 | 110.54M shares 10-K · filed 2026-03-03 |
| 2025-10-27 | 109.82M shares 10-Q · filed 2025-11-06 |
| 2025-07-28 | 89.17M shares 10-Q · filed 2025-08-07 |
| 2025-04-28 | 89.14M shares 10-Q · filed 2025-05-08 |
| 2025-02-28 | 88.60M shares 10-K · filed 2025-03-04 |
| 2024-10-31 | 68.55M shares 10-Q · filed 2024-11-07 |
| 2024-07-31 | 68.08M shares 10-Q · filed 2024-08-08 |
| 2024-04-30 | 68.01M shares 10-Q · filed 2024-05-09 |
| 2024-02-12 | 67.78M shares 10-K · filed 2024-02-22 |
| 2023-11-06 | 67.52M shares 10-Q · filed 2023-11-09 |
| 2023-08-07 | 67.38M shares 10-Q · filed 2023-08-10 |
| 2023-05-08 | 67.18M shares 10-Q · filed 2023-05-11 |
| 2023-03-08 | 66.72M shares 10-K · filed 2023-03-13 |
| 2022-11-07 | 66.26M shares 10-Q · filed 2022-11-10 |
| 2022-08-08 | 58.53M shares 10-Q · filed 2022-08-11 |
| 2022-05-09 | 58.53M shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |